Subsequent in vitro work explored the effects of both everolimus and the ATP-competitive mTOR inhibitor PP242 alone or in combination with JAK inhibitors (JAKi) in both murine and human JAK2V617F-mutated cell lines and primary MPN progenitor cells. This evidence concerns the gene MTOR and myeloproliferative neoplasm.